Author

W. Nicholson Price II

  • Bioethics

    FSMA Conference Part 2: FSMA and Risk Regulation Strategy

    By W. Nicholson Price [Ed. Note: On Friday, the Petrie-Flom Center, the Food Law and Policy Clinic (a division of the Center for Health Law and Policy Innovation), the Food Law Lab, and the Harvard Food Law Society (with support from…

    FSMA Conference Part 2: FSMA and Risk Regulation Strategy

  • Biotechnology

    Patent trolls/Monetizers/PAEs/NPEs and Bio/Pharma

    By Nicholson Price There’s recently been a lot of focus on patent trolls (so called by those who dislike them; they’re also known as patent assertion entities, nonpracticing entities, and monetizers, each with slightly different…

    Patent trolls/Monetizers/PAEs/NPEs and Bio/Pharma

  • FDA

    More on drug quality: India

    By Nicholson Price The New York Times had a troubling piece this weekend about major problems in drug quality in India, where FDA Commissioner Margaret Hamburg is visiting to discuss safety issues. India makes 40%…

    More on drug quality: India

  • FDA

    Drug shortages continue: new report

    By Nicholson Price The GAO released a report yesterday on the continuing problem of drug shortages, which unfortunately seem like they’re becoming a permanent part of the U.S. healthcare system.  Hundreds of drugs have at least…

    Drug shortages continue: new report

  • Cloning

    Three Parents and a Baby

    By Nicholson Price There’s an interesting post up on the New York Times’ Well Blog about children with three biological parents—in this case, three genetic parents.  Here, a mother and a father provided chromosomal DNA…

    Three Parents and a Baby

  • Health Care Finance

    Great piece on ER pricing

    By Nicholson Price The New York Times has posted another installment of its excellent series, “Paying Till it Hurts,” by Elisabeth Rosenthal, this time on the astonishingly high costs of emergency room visits.  The piece…

    Great piece on ER pricing

  • Food

    Significant paper on GMO food risks retracted

    By Nicholson Price In the debate over whether genetically modified organisms should be allowed in the food supply or labeled when they’re used, a central question is whether GMOs are any more dangerous to people…

    Significant paper on GMO food risks retracted

  • Intellectual Property

    Losing antibiotics

    By Nicholson Price Antibiotics are a crucial aspect of modern medicine, and this fall has been filled with a number of hugely troubling reports about how we’re moving closer to an era where we can…

    Losing antibiotics

  • Bioethics

    GIM: Informed consent for return of incidental findings in genomic research

    By Nicholson Price In the second installment of our new collaboration with Genetics in Medicine, we are highlighting an article released last week discussing informed consent for the return of incidental findings in genomic research.…

    GIM: Informed consent for return of incidental findings in genomic research

  • FDA

    Foodborne illness and the government shutdown

    By Nicholson Price This story is still developing, so this post will just be a quick pointer.  You may have seen news stories about how FDA isn’t inspecting foods, and 90% of seafood isn’t getting…

    Foodborne illness and the government shutdown